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Evaluation of the 3-drug combination, Rifater,
versus 4-drug therapy in the ambulatory treatment
of tuberculosis in Cape Town
Abstract The subjective iInpression among clinicians that
the use of Rifater was causing delayed sputum
conversion and increased drug resistance was
tested in a prospective study. Adults in the Cape
Town municipal area with a first episode of pul-
monary tuberculosis were treated either with
Rifater or a regimen consisting of isoniazid,
rifampicin, pyrazinamide and ethambutol. All
patients who took the treatment as prescribed (67
Rifater, 39 the 4-drug regimen) converted to a
negative sputum culture by the titne 90 doses had
been taken. The rates of inadequate compliance
and ofside-effects were siInilar in the two groups.
Drug sensitivity testing of bacteria cultured
from pre-treatment sputum speciInens revealed
an overall primary resistance rate of 4,84% in the
population studied, sufficiently low to preclude
any necessity for routine pre-treatment drug sen-
sitivity testing.
S Air Med J 1994; 84: 325·328.
TIe combination drug Rifater (isoniazid 80 mg,pyrazinamide 250 mg, rifampicin 120 mg) wasintroduced in Cape Town tuberculosis clinics in
mid-1988. It was to be used as sole therapy for ambula-
tory patients over 7 years of age in whom tuberculosis
was diagnosed for the first time. Prior to the introduc-
tion of Rifater, such patients were given 4-drug therapy
with isoniazid (Th.TH), pyrazinamide (PZA), rifampicin
(RIF) and either ethambutol (EMB) or streptomycin
(SMN). PZA was given for 60 doses and SMN for 90
doses. RIF and INH were administered, as is Rifater, for
a total of 130 doses; treatment was given 5 days a week.
After Rifater was introduced, a subjective impression
began to emerge among medical staff that it was not as
effective as the old 4-drug regimens; there appeared to
be more culture-positive cases at the 90-dose stage and
some of these demonstrated resistance to one or more
drugs. As a result, an increasing number of patients
were being given EMB in addition to Rifater, and rou-
tine pre-treatment sensitivity testing was introduced.
This added to the expense of treatment and placed an
additional load on the laboratory.
Prompted by these observations, a literature search
was conducted. This revealed that the efficacy of 3-drug
regimens (INH, PZA and RIF administered as separate
preparations) had been demonstrated1,2 but that there
was considerable variation in dose and duration of ther-
apy with the individual drugs, as well as supervision and
hospitalisation. Combination tablets for daily therapy
had been studied in several countries3-8 but composition
of the tablets varied, as did the population and study
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parameters. In general, no significant difference was
found between Rifater and regimens of 3 or more sepa-
rate drugs. The combination tablet also appeared to be
effective when pre-treatment resistance to 1 of the drugs
(usually INH) existed,4,5 but these authors recom-
mended that treatment be augmented or adjusted in
such cases.
In South Africa, Cowie and Brink' compared the
locally available form of Rifater with 'regimen l' (Th.TH,
PZA, RIF and SMN) and found Rifater 'effective,
acceptable and free of side-effects'. However, sputum
conversion was not routinely checked in this study,
treatment was given for only 100 days, and the popula-
tion differed from that in Cape Town. Compliance with
the simpler Rifater regimen, contrary to expectations,
was worse than in the regimen 1 group. The authors
considered this to be due to differences in supervision of
the two groups. Glatthaar et al. 10 compared Rifater with
'regimen 2' (INH, PZA, RIF and EMB given as sepa-
rate preparations). Sputum conversion rates and 2-year
relapse rates were comparable but relative compliance
rates were not discussed.
An imponant determinant of treatment outcome,
mentioned in many studies, is the drug resistance rate
in the local population. No reliable rates were available
for the western Cape. Nationally, primary resistance
to INH was calculated at 9,5% in a survey of black
adults in the Transvaal, Orange Free State, Natal and
the eastern Cape. II
This study aimed to test subjective impressions of
treatment outcomes with Rifater compared with a previ-
ous standard regimen, regarding: (I) primary drug resis-
tance; (iz) sputum bacteriological conversion rates; (iil)
compliance; and (iv) side-effects, under conditions pre-
vailing at community-based tuberculosis clinics.
Subjects and methods
A prospective study was peiformed to compare Rifater
with the old schedule II (INH, PZA, RIF and EMB).
The purpose was to study the efficacy of the two regi-
mens under the practical circumstances prevailing in the
municipal clinics. No changes were made to normal
clinic routine or to management protocols, so both
patient and doctor knew which prescription each indi-
vidual received. No significant bias was expected since
management protocols were defined in detail and out-
comes were measured by means of objective tests.
Subjects and sampling
Subjects were coloured patients over the age of 15 years,
with a first episode of pulmonary tuberculosis, diag-
nosed by means of a chest radiograph and a positive
sputum culture. Those with additional non-tuberculous
pathology were excluded, as were pregnant women.
Clinic numbers, issued by a clerk in order of arrival,
were used to allocate treatment regimens to those who
satisfied the inclusion criteria. Odd numbers received
Rifater and even numbers schedule II. Thereafter the
routine management plan was followed. The investiga-
tors hoped to collect 100 subjects in each treatment
group in order to demonstrate any clinically significant
differences.
Treatment was given 5 days a week for 130 doses.
Side-effects
Side-effects were recorded and if treatment was
changed, the patient was then excluded from the trial.
TreatInent
Treatment regimens are detailed in Table I. No other
drugs were routinely prescribed apart from an injectable
contraceptive in women of child-bearing age.
Compliance
Supervisors administered and recorded treatment at
work or in the clinics. Any patient not taking at least
75% of the possible dose for the month was classed as
non-compliant and dropped from the study. Any other
reasons for withdrawal (e.g. transfer out of area) were
recorded as they occurred.
TABLE 11.
Classification of patients dropped from trial
Rifater Schedule II
Admitted to trial 173 146
Dropped from trial
No pre-treatment sensitivities 4 5
Poor compliance 39 32
Admitted to hospital 4 4
Transferred out of area 4 4
Primary rifampicin resistance 1 1
Treatment changed because
of complaints of 'side-effects'
(before 90 doses) 10 8
No 90-dose culture result 15 8
Deviation from protocol 9 4
Became pregnant 0 3
Ethambutol unavailable N/A 38
Follow-up not completed 20 N/A
-
106 107
Suitable for analysis of 90-dose results 67 39
173 146
Three hundred and nineteen patients were admitted to
the trial between April 1990 and August 1991. There
was a high attrition rate for a variety of reasons (Table
IT) and the target of 200 patients successfully complet-
ing treatment as per protocol was not achieved. A pre-
mature termination of the study was necessitated when
EMB became unavailable. Results of patients who did
not receive EMB throughout were not included in the
analysis, except for their pre-treatment sensitivities.
Follow-up of those patients on Rifater who had not
completed treatment by mid- ovember 1991 was dis-
continued for practical reasons.
Results
Pre-treatnlent sputum sensitivities. Results were
obtained for 310 patients. Fifteen patients (4,8%) were
infected with bacteria resistant to one or more of the
drugs tested (Table III). For various reasons unrelated
to efficacy of treatment, none of these patients (5 on




RIF 450 mg « 50 kg)
600 mg (;> 50 kg)
PZA 30 mg/kg (to nearest
upper 250 mg; max. 2 g)
EMB 20 mg/kg (to nearest
upper 100 mg)
Rifater
1 tablet/10 kg body





The pre-treatment drug sensitivity report was usually
received about 6 weeks after the start of treatment.
Patients who had a resistance to RIF required a major
alteration in therapy and were withdrawn from the trial.
Other resistant cases were to be retained in the trial
without alteration in therapy but with monthly clinical
and bacteriological reassessments. Adjustments would
be made if further resistances emerged. (In fact, no such
cases were encountered.)
Number of patients with a positive sputum cul-
ture after 90 doses. In both treatment groups, all
patients who had taken their medication according to
protocol had a negative sputum culture by 90 doses.
Non-cOInpliance rate. Most cases of inadequate
compliance had already occurred by 90 doses. Four
patients on Rifater and 2 on schedule IT defaulted after
the 90-dose stage. Although the percentage of non-com-
pliance on schedule IT (43,0%) appeared considerably
higher than the percentage on Rifater (35,5%), the
difference was not statistically significant (X2 = 0,84,
P = 0,36; OR = 1,37, Cl 0,74 - 2,55) (Table IV).
Investigations
The following were performed on all patients: (x) before
commencement of therapy - chest radiography, spu-
tum microscopy and culture, and assessment of drug
sensitivities; (ix) after about 90 doses of treatment (with-
in the range of 80 - 100 doses) - a radiograph, sputum
culture and assessment of sensitivities; (iix) at 130 doses
(acceptable range 125 - 135 doses) - treatment was
discontinued in those patients who had a negative 90-
dose culture result.
Sputum testing was performed at the South African
Institute for Medical Research by means of established
methods. 12 Specimens submitted for sensitivity tests
were examined for sensitivity to INH, RIF, SMN, EMB
and ethionamide. Radiographs were read by medical
officers managing the patients.
Ethics
Both groups of patients received approved regimens. In
cases where drug resistance (other than RIP) occurred,
patients would have received at least two effective drugs.
This was demonstrated by Brandli ec al. 7 as adequate to
achieve clinical cure. Since Rifater has been approved
for use without prior investigation of drug resistance,







INH + RIF + EMB
Streptomycin alone
Total
Total patients with INH resistance
Total patients with rifampicin resistance
Total specimens analysed; 310.





















• This denominator consists of all patients with known outcome and who were
managed according to protocol, viz. non-compliant patients, those with no 90-













The incidence of proven side-effects was very low in
both groups. The incidence might have been higher as
there were many more complaints. However, these were
not proven, as the prescribed system of management
(re-challenging with separate drugs) was not followed in
all cases. In addition, in several patients, other confusing
factors such as excess alcohol intake were present.
These could not be discounted as the cause of the
symptoms.
Discussion
• This denominator consists of those whose treatment was changed because of
side-effects, those with no 90-dose culture result, and those suitable for analysis
(Table 11).
Side-effects. A total of 147 patients (92 Rifater, 55
schedule II) were observed for the full period of therapy.
Eighteen (10 Rifater, 8 schedule II) complained of
symptoms which could have been due to treatment
(Table V). A direct relationship was demonstrated
between drugs and 'side-effects' in only 3 cases. Two
patients on Rifater reacted to INH when re-challenged
with the drugs separately Cl rash, 1 jaundice) and one
on schedule IT developed a rash due to EMB. There was
no significant difference between the two treatment
groups in respect of incidence of complaints (X' =0,16,
P =0,69) or side-effects (Fisher's exact test, P =0,69).
In spite of not achieving the target of 100 patients com-
pleting each treatment regimen, numbers were sufficient
to reflect any clinically important differences. No patient
failed to achieve sputum conversion by 90 doses pro-
vided medication was taken regularly. Assessment of
chest radiographs performed at 90 doses showed either
improveI11ent Or occasionally (those with minimal
lesions) no change, for all these cases. In spite of this, a
considerable numb~r of patients received treatment for
longer than th.e staI1dard 130 doses. Review of these
patients' records kg to Ih~ 90nclusion that the labelling
of a patient's progress as unsatisfactory (one of the origi-
nal reasons for the study) was a reflection of individual
prescribing habits and not based upon documented
unsatisfactory progress.
The primary drug resistance rate was low, indicating
that in adult coloureds in the western Cape who have
not previously suffered from mberculosis, there should
be no hesitation in prescribing standard regimens with-
out performing pre-treatment bacterial sensitivity tests.
The non-compliance rate was high in both groups.
There appeared to be poorer compliance on schedule IT
but this was not statistically significant. Although larger
sample sizes might have demonstrated a small difference
between the two, this finding was in keeping with previ-
ous subjective observations that no noticeable improve-
ment had occurred when Rifater was introduced. It is
most important to note that few of these non-compliant
patients 'dropped out' altogether. Although they were
excluded from further follow-up in the trial, the majority
did eventually complete a course of therapy. The non-
compliance rate of the study is therefore not an index of
'case holding' in these clinics.
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Risk factors for the development of osteoporosis in a
South African population
A prospective analysis
R. BLAAUW, E. C. ALBERTSE, T. BENEKE, C. J. LOMBARD, R. LAUBSCHER,
F.S.HOUGH
Abstract Despite the vast number of risk factors that appa-
rently predispose to the development ofosteoporo-
sis (OP), they have not been accurately identified
and given relative priority. In order to analyse
possible risk factors prospectively in a local
patient population with overt OP (histOInorpho-
metrically confirmed and characterised) and com-
pare it with an appropriately matched non-OP
control group (with normal bone mass on dual-
energy X-ray absorptiometry), a detailed general
history, risk factor analysis, dietary history and
anthropometric data were obtained from 56 OP
and 125 non-OP subjects. In females a positive
family history ofOP (P =0,002), a fair complexion
(P =0,009), lower body mass (P =0,02) and height
(P =0,03), no breast-feeding of babies (P =0,006),
a history of smoking (P = 0,001) and fat distribu-
tion around the waist (P =0,009) were identified as
risk factors. In males lack of exercise (P =0,008), a
history of smoking (P =0,01), lower body mass
(P = 0,04) and height (P = 0,04), a preference for
salty· food (P =0,02) and fat distribution around
the waist (P =0,002) appeared to predispose.
Dietary calcium, phosphorus, protein and caffeine
intakes were similar in OP and control subjects,
but alcohol consumption was clearly higher in
both OP males (P = 0,001) and females (P = 0,01).
S Afr Med J 1994; 84: 328-332.
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O
steoporosis (OP) and associated fractures are
endemic in Western societies, with prevalence
rates approximating 50% among elderly white
women, a mortality rate of 12 - 25% in patients with hip
fractures, and annual costs of some $7 billion in the
USA alone. 1 Although it clearly constitutes a major
health problem, the exact incidence and magnitude of
the OP syndrome in South Africa is as yet unknown.
Since OP usually becomes manifest at a late stage
when the patient has lost more than 50% of his/her
skeletal mass, early detection and imp1ementation of
prophylactic measures are essential. This is, however,
complicated by the fact that bone loss is undetectable by
routine radiographs until at least 30 - 40% of the bone
mass has been lost. Moreover, the more reliable and
accurate methods of measuring bone mass, such as
dual-energy X-ray absorptiometry (DEXA), are expen-
sive and not readily available.2 Ideally, the identification
of historical risk factors of a person's predisposition to
develop OP, followed by DEXA examination of those at
risk, should be undertaken.
Although a large number of possible risk factors for
the development of OP are known, studies to date have
generally been unsuccessful in identifying and giving
relative priority to those risk factors that are most impor-
tant in a specific community. Moreover, since OP is a
heterogeneous syndrome and not a single disease entity,
different risk factors may pertain to different subsets of
OP.
This study aimed to analyse possible risk factors
prospectively in a local patient population with overt
primary OP and to compare it with an appropriately
matched non-OP control group_
Subjects and methods
Subjects
All the subjects in the OP group had proven idiopathic
('primary') OP, detected by DEXA as well as clinical
examination, a skeletal survey, quantitative histomor-
phometric examination of undeca1cified bone biopsies
and a full biochemical work-up. The group consisted of
56 subjects, consecutively admirted to our metabolic
